Havrix Adulti (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Adulti is indicated for active immunization against hepatitis A virus in individuals who are at risk of infection. It is used in various clinical settings to provide protective immunity.

• Primary prevention of hepatitis A in adults and adolescents.
• Travel-related protection for persons visiting endemic regions.
• Outbreak control in community or institutional settings.
• Pre-exposure prophylaxis for healthcare workers handling hepatitis A cases.
• Immunization of individuals with chronic liver disease to reduce disease severity.

Side effects of Havrix Adulti are generally mild to moderate and resolve without medical intervention. Serious adverse events are rare but should be reported to a healthcare professional.

Common

• Injection site pain, redness, or swelling.
• Low-grade fever occurring within 24‑48 hours.
• Headache or mild fatigue after vaccination.
• Muscle aches or joint discomfort.
• Nausea or mild gastrointestinal upset.

Serious

• Severe allergic reaction (anaphylaxis) with difficulty breathing or swelling of the face.
• Neurological symptoms such as Guillain‑Barré syndrome.
• Persistent high fever lasting more than 48 hours.
• Unexplained bleeding or bruising at the injection site.
• Signs of infection such as pus or increasing redness.

Before receiving Havrix Adulti, certain precautions should be considered to ensure safety and optimal immune response.

• Verify no known severe allergy to any vaccine component, including gelatin or latex.
• Defer vaccination in individuals with acute moderate or severe illness.
• Counsel pregnant women that the vaccine is classified as Category B; discuss risk‑benefit with a provider.
• Use with caution in immunocompromised patients; immune response may be reduced.
• Review history of Guillain‑Barré syndrome; consider alternative strategies if present.
• Ensure proper storage and handling to maintain vaccine potency.

Havrix Adulti may interact with other medications or vaccines, influencing efficacy or safety.

Avoid

• Concurrent administration with live viral vaccines without appropriate interval.
• Use of immunoglobulins or blood products within 14 days before or after vaccination, as they may diminish immune response.

Use with caution

• Administration alongside other inactivated vaccines; monitor for increased local reactions.
• Patients receiving immunosuppressive therapy; assess antibody response.
• Antipyretics taken prophylactically; may mask fever as a sign of reaction.
• Chronic corticosteroid use; may require additional dosing for adequate protection.